HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 01.wnl.0000316195.52001.e1v1 71/15/1142    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Wang, H. Articles by Ascherio, A. PubMed PubMed Citation Articles by Wang, H. Articles by Ascherio, A. Related Collections Harm/ risk (analysis) Multiple sclerosis Case control studies Related Article

Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults

From the Departments of Nutrition (H.W., K.L.M., E.J.O., A.A.) and Epidemiology (A.A.), Harvard School of Public Health, Boston; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School (A.A.), Boston, MA; Clinical Department of Neurology (M.R., T.B.), Innsbruck Medical University, Austria; and Division of Preventive Medicine (L.I.L.), Walter Reed Army Institute of Research, Silver Spring, MD.

Address correspondence and reprint requests to Dr. Hao Wang, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115 hwang{at}hsph.harvard.edu

Background: It remains uncertain whether the presence of serum anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in healthy individuals contributes to predict their risk of developing multiple sclerosis (MS).

Methods: Prospective, nested case-control study of more than 7 million US military personnel who have serum samples stored in the Department of Defense Serum Repository. A total of 126 MS cases and 252 controls matched by age, sex, race/ethnicity, and dates of blood collection were included in the analysis. An ELISA was used to detect IgM and IgG antibodies to MOG. Analyses were conducted with and without adjustment for serum titers of antibodies to the Epstein-Barr nuclear antigen (EBNA), which are an established risk factor for MS.

Results: The presence of anti-MOG IgG antibodies in serum was associated with an increase in risk of developing MS (relative risk for anti-MOG IgG+/IgM– vs seronegativity to both anti-MOG IgM and IgG: 2.03; 95% CI: 1.19–3.46; p = 0.01). This association, however, was attenuated and no longer significant after adjustment for titers of antibodies to EBNA, which were higher among individuals positive for anti-MOG antibodies.

Conclusion: Our findings suggest that although individuals with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have an increased risk of developing multiple sclerosis, this association may at least in part reflect cross-reactivity between MOG and Epstein-Barr nuclear antigen.

Abbreviations: CIS = clinical isolated syndrome; DoDSR = US Department of Defense Serum Repository; EBNA = Epstein-Barr nuclear antigen; EBV = Epstein-Barr virus; MBP = myelin basic protein; MOG = myelin oligodendrocyte glycoprotein; MS = multiple sclerosis; RR = relative risk.

Editorial, page 1132

e-Pub ahead of print August 27, 2008, at www.neurology.org.

Supported by NIH/National Institute of Neurological Disorders and Stroke grant R01 NS042194: prediagnostic markers of infection and risk of MS.

Disclosure: The authors report no disclosures.

Received December 5, 2007. Accepted in final form March 11, 2008.

Related Article

Cross-reactivity between epidemiology and immunology in multiple sclerosis

Amit Bar-Or and Jack Antel
Neurology 2008 71: 1132-1133. [Full Text] [PDF]

This article has been cited by other articles:

				A. Bar-Or and J. Antel Cross-reactivity between epidemiology and immunology in multiple sclerosis Neurology, October 7, 2008; 71(15): 1132 - 1133. [Full Text] [PDF]